This article was originally published in The Tan Sheet
MiraLAX laxative launched in February helped drive Consumer Health Care third-quarter sales up 5% to $273 mil., Schering-Plough reports during Oct. 22 analyst call. The brand is second in its category in the U.S. with a 7% market share, the firm says. Trailing market leader Metamucil in the laxative/stimulant segment, MiraLAX had dollar sales of $12.1 mil. in food, drug and mass retailers for the 13 weeks ended Sept. 30, according to IRI data. MiraLAX was the first Rx-to-OTC switch in the laxatives category in over 30 years (1"The Tan Sheet" Dec. 11, 2006, p. 7). Also driving growth was Claritin (loratadine) with sales up 9% to $104 mil. OTC sales grew 17% to $162 mil., offset by a 33% decline in sun care sales. Adjusted net revenues increased 12% to $3.5 bil. and profit was $713 mil...
You may also be interested in...
Schering-Plough will position Braintree Laboratories' MiraLAX laxative as an effective treatment for occasional constipation without "harsh" side effects linked to other OTC laxative products
Jessica O’Connell, partner at Covington & Burling, is getting questions from clients about the electronic system the FDA plans to launch in coming weeks for cosmetics manufacturers to register facilities and list products as required by new cosmetics regulations. It remains to be seen how hard the 29 December 2023 deadline will be for companies to get their information submitted.
Programs only allowed for brands with generic competition under court ruling, but related programs such as copay maximizers and so-called ‘alternative funding’ programs are not directly impacted by the decision.